HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ibopamine challenge test can be used to differentiate glaucoma suspects from glaucoma patients.

AbstractBACKGROUND:
Many countries face the challenge of a rising number of patients with or at risk of developing glaucoma. A test to differentiate between people who are unlikely to develop glaucoma and those at risk for the disease could be clinically useful. Ibopamine, when administered topically, temporarily increases aqueous production. Normal eyes with healthy trabecular meshwork show no significant change in intraocular pressure (IOP) following an ibopamine challenge; however, those with glaucoma demonstrate elevated IOP.
DESIGN:
The study was designed as a prospective case-control study in a tertiary hospital.
PARTICIPANTS:
Patients were recruited consecutively as they presented to glaucoma clinics at Flinders Medical Centre (n = 39); the sample included 18 glaucoma suspects and 21 patients with glaucoma. All patients had open anterior chamber angles and no evidence of secondary glaucoma.
METHODS:
Patients underwent IOP measurements followed by instillation of ibopamine 2% solution and subsequent repeated IOP assessment. The difference between the baseline measurement and that taken at 45 min was determined and compared between groups.
MAIN OUTCOME MEASURE:
The outcome measure was the positivity of the ibopamine challenge test, defined by an increase in IOP > 3 mmHg.
RESULTS:
We observed a mean increase in IOP of 1.9 ± 1.6 mmHg or 12.5 ± 10.3%) for glaucoma suspects and 7.4 ± 4 mmHg or 52.4 ± 26.5% for glaucoma patients (P < 0.0001). Four glaucoma suspects (22%) and 19 glaucoma patients (90%) tested positive (P < 0.0001).
CONCLUSION:
This study demonstrates that ibopamine has potential as a test to differentiate glaucoma suspects from patients with glaucoma.
AuthorsKatja Ullrich, Jamie E Craig, John Landers
JournalClinical & experimental ophthalmology (Clin Exp Ophthalmol) 2014 May-Jun Vol. 42 Issue 4 Pg. 342-6 ISSN: 1442-9071 [Electronic] Australia
PMID24034130 (Publication Type: Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2013 Royal Australian and New Zealand College of Ophthalmologists.
Chemical References
  • Dopamine Agonists
  • Mydriatics
  • Ophthalmic Solutions
  • ibopamine
  • Deoxyepinephrine
Topics
  • Administration, Topical
  • Aged
  • Case-Control Studies
  • Deoxyepinephrine (analogs & derivatives)
  • Dopamine Agonists
  • Female
  • Glaucoma, Open-Angle (diagnosis)
  • Humans
  • Intraocular Pressure (drug effects)
  • Male
  • Mydriatics
  • Ocular Hypertension (diagnosis)
  • Ophthalmic Solutions
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: